Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Iovance Biotherapeutics (NASDAQ:IOVA) and raises the price target from $18 to $22.
February 29, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Iovance Biotherapeutics and increases the price target from $18 to $22.
The upgrade in the price target by a reputable analyst like Peter Lawson from Barclays indicates a strong confidence in Iovance Biotherapeutics' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100